Human Siglec-9 Antibody Summary
Siglec‑E is observed and less than 1% cross-reactivity with recombinant human (rh) Siglec-3, rhSiglec-5, rhSiglec-6, rhSiglec-7, rhSiglec-8 or rhSiglec-10 is observed. In Western blots, approximately 100% cross-reactivity with recombinant mouse Siglec‑E is observed under
Accession # Q9Y336
Human Siglec-9 Sandwich Immunoassay
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.
Detection of Siglec‑9 in Human Blood Granulocytes by Flow Cytometry. Human peripheral blood granulocytes were stained with (A) Mouse Anti-Human Siglec-3/CD33 PE-conjugated Monoclonal Antibody (Catalog # FAB1137P) and (B) Mouse Anti-Human Siglec-9 Monoclonal Antibody (Catalog # MAB1139, filled histogram) or isotype control antibody (Catalog # MAB003, open histogram), followed by PerCP-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # F0114).
Cell Adhesion Mediated by Siglec‑9 and Neutralization by Human Siglec‑9 Antibody. Recombinant Human Siglec-9 Fc Chimera (Catalog # 1139-SL), immobilized onto a microplate, supports the adhesion of human red blood cells in a dose-dependent manner (orange line). Adhesion elicited by Recombinant Human Siglec-9 Fc Chimera (10 µg/mL) is neutralized (green line) by increasing concentrations of Mouse Anti-Human Siglec-9 Monoclonal Antibody (Catalog # MAB1139). The ND50is typically 0.015-0.075 µg/mL.
Preparation and Storage
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Siglecs(1) (sialic acid binding Ig-like lectins) are I-type (Ig-type) lectins belonging to the Ig superfamily. They are characterized by an N-terminal Ig-like V-type domain which mediates sialic acid binding, followed by varying numbers of Ig-like C2-type domains (1, 2). Eleven human Siglecs have been cloned and characterized. They are sialoadhesin/CD169/Siglec-1, CD22/Siglec-2, CD33/Siglec-3, Myelin-Associated Glycoprotein (MAG/Siglec-4a) and Siglec-5 to -11 (1‑4). To date, no Siglec has been shown to recognized any cell surface ligand other than sialic acids, suggesting that interactions with glycans containing this carbohydrate are important in mediating the biological functions of Siglecs. Siglecs 5 to 11 share a high degree of sequence similarity with CD33/Siglec-3 both in their extracellular and intracellular regions. They are collectively referred to as CD33-related Siglecs. One remarkable feature of the CD33-related Siglecs is their differential expression pattern within the hematopoietic system (2, 3). This fact, together with the presence of two conserved immunoreceptor tyrosine-based inhibition motifs (ITIMs) in their cytoplasmic tails, suggests that CD33-related Siglecs are involved in the regulation of cellular activation within the immune system.
The cDNA of human Siglec-9 encodes a 463 amino acid (aa) polypeptide with a hydrophobic signal peptide, an N-terminal Ig-likeV-type domain, two Ig-like C2-type domains, a transmembrane region and a cytoplasmic tail (5, 6). In peripheral blood leukocytes, Siglec-9 is expressed on neutrophils, monocytes, a fraction of NK cells, B cells, and a minor subset of CD8+ T cells (5). It binds equally well to both 2,3- and 2,6-linked sialic acid (5, 6). Siglec-9 is closely related to Siglec-7, and they share ~80% amino acid sequence identity. The gene encoding siglec-9 was mapped to chromosome 19q13.4.
- Crocker, P.R. et al. (1998) Glycobiology 8:v.
- Crocker, P.R. and A. Varki (2001) Trends Immunol. 22:337.
- Crocker, P.R. and A. Varki (2001) Immunology 103:137.
- Angata, T. et al. (2002) J. Biol. Chem. 277:24466.
- Zhang, J.Q. et al. (2000) J. Biol. Chem. 275:22121.
- Angata, T. et al. (2000) J. Biol. Chem. 275:22127.
Citations for Human Siglec-9 Antibody
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
Citations: Showing 1 - 3
Filter your results:
Siglec-9 regulates an effector memory CD8+ T-cell subset that congregates in the melanoma tumor microenvironment
Authors: Q Haas, K Frias Boli, C Jandus, C Schneider, C Simillion, MA Stanczak, M Haubitz, SM Seyed Jafa, A Zippelius, GM Baerlocher, H Läubli, RE Hunger, P Romero, HU Simon, S von Gunten
Cancer Immunol Res, 2019;0(0):.
Sample Types: Whole Cells
Applications: Flow Cytometry
Self-associated molecular patterns mediate cancer immune evasion by engaging Siglecs on T cells
Authors: MA Stanczak, SS Siddiqui, MP Trefny, DS Thommen, KF Boligan, S von Gunten, A Tzankov, L Tietze, D Lardinois, V Heinzelman, MS von Bergwe, W Zhang, HJ Lenz, Y Han, CI Amos, M Syedbasha, A Egli, F Stenner, DE Speiser, A Varki, A Zippelius, H Läubli
J. Clin. Invest., 2018;0(0):.
Sample Types: Whole Cells
Molecular mimicry of host sialylated glycans allows a bacterial pathogen to engage neutrophil Siglec-9 and dampen the innate immune response.
Authors: Carlin AF, Uchiyama S, Chang YC, Lewis AL, Nizet V, Varki A
Sample Types: Whole Cells
No product specific FAQs exist for this product, however you mayView all Antibody FAQs
Reviews for Human Siglec-9 Antibody
There are currently no reviews for this product. Be the first to review Human Siglec-9 Antibody and earn rewards!
Have you used Human Siglec-9 Antibody?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image